
Ypsomed Holding AG
YPHDF
Updated: 24/09/2026, 04:32:47
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
No summaries found.
- Share price
- $436.55
- Market cap
- $5.74B
- Exchange
- OTC
- Currency
- USD
- CEO
- Simon Michel
- Employees
- 2,025
- IPO date
- 17/08/2022
- Beta
- 0.77
- Last dividend
- $0.00
- Day range
- $367.87 – $436.55
- 52-week range
- $354.92 – $501.00
- 1-day performance
- 0.00%
- 1-year performance
- 23.00%
- Current drawdown (1Y)
- -12.86%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- CH0019396990
- Created
- 07/12/2025, 15:12:34
- Last update
- 24/09/2026, 04:32:47
Track Ypsomed Holding AG with an AI analyst
See which prediction-market events move YPHDF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.